poisar

Stocks · News reference

Disappointing Data Prompts GSK to Drop Cough Drug Development

BenzingaJul 17, 2026, 2:48 PMVandana Singh

GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testing it for irritable bowel disease.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 17, 2026, 2:48 PM
Checked
Jul 17, 2026, 2:48 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading